Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
Resource Type
Article
Authors
Williams, Bryan ; Turner, Rebecca ; Libri, Vincenzo ; Mussai, Francis ; Middleton, Gary ; Bowden, Sarah ; Bangash, Mansoor ; Gao-Smith, Fang ; Patel, Jaimin ; Sapey, Elizabeth ; Thomas, Mark ; Coles, Mark ; Watkinson, Peter ; Rahman, Naj ; Angus, Brian ; Mentzer, Alexander J. ; Novak, Alex ; Feldman, Marc ; Richter, Alex ; Faustini, Sian ; Bathurst, Camilla ; Van de Wiel, Joseph ; Mee, Susie ; James, Karen ; Rahman, Bushra ; Turner, Karen ; Hill, Adam ; Gordon, Anthony ; Yap, Christina ; Matthay, Michael ; McAuley, Danny ; Hall, Andrew ; Dark, Paul ; McMichael, Andrew ; Fisher, Benjamin A ; Veenith, Tonny ; Slade, Daniel ; Gaskell, Charlotte ; Rowland, Matthew ; Whitehouse, Tony ; Scriven, James ; Parekh, Dhruv ; Balasubramaniam, Madhu S ; Cooke, Graham ; Morley, Nick ; Gabriel, Zoe ; Wise, Matthew P ; Porter, Joanna ; McShane, Helen ; Ho, Ling-Pei ; Newsome, Philip N ; Rowe, Anna ; Sharpe, Rowena ; Thickett, David R ; Bion, Julian ; Gates, Simon ; Richards, Duncan ; Kearns, Pamela
Source
In The Lancet Respiratory Medicine March 2022 10(3):255-266
Subject
Primary Research Articles
Language
ISSN
2213-2600